AstraZeneca India rebrands Global Technology Centre as Global Innovation and Technology Centre

The rebranding marks the centre's evolution of capabilities, commitment to driving innovation and moving the company towards a digitally-enabled future.

Published On 2022-04-08 07:35 GMT   |   Update On 2022-04-08 07:37 GMT
Advertisement

Chennai: AstraZeneca India Private Limited, the Global Capability Centre (GCC) of AstraZeneca has announced that they have repositioned their Global Technology Centre (GTC) to focus on driving increased innovation, resulting in a rebrand of the centre to Global Innovation and Technology Centre (GITC).

Over the last eight years, the GTC in Chennai has consistently delivered market-leading IT services and capabilities for AstraZeneca's global business. Since inception, the centre has evolved its offering from that of traditional IT services, into a critical engine for AstraZeneca's digital journey and ongoing source of technology innovation.

Advertisement

The Chennai centre has played a key role in driving productivity, simplification, technology delivery and innovation across AstraZeneca's business and in support of life-changing medicines delivered to patients worldwide. "The rebranding marks the centre's evolution of capabilities, commitment to driving innovation and moving the company towards a digitally-enabled future," the company said in its release.

Cindy Hoots, Chief Digital Office and CIO, AstraZeneca, said, "We live in an era where the possibilities of digital and technology to transform the lives of patients and the healthcare sector, are limitless. Our centre in Chennai continues to play a strategic role in our digital transformation, working on Visualisation, Data & Analytics, Hyperautomation, XR/VR Capabilities, among other areas. These technologies and innovations play a key role in helping us to advance our science, anticipate patient needs, and work seamlessly across our organization. I am thrilled to see that the work delivered by the team in Chennai is being reflected in our transition from GTC to GITC."

Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited (AZIPL), said: "The healthcare and life sciences industry is facing unprecedented challenges and opportunities. Over the last few years, we have successfully expanded our skillset and expertise from providing IT services, to becoming a pivotal global centre driving innovation and transformation. With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country. The strong collaboration we have been able to build between industry, academia and the government has helped us in our pursuit of enabling smart capabilities at scale across the company's value chain. Our GITC aims to bring the best of technology, innovation and people to the forefront, to address the ever-evolving healthcare and technology landscape. The rebranding is a powerful acknowledgement of the strategic importance our Chennai centre plays in our global operations."

Read also: AstraZeneca's Young Health Program opens 3 Health Information Centres (HICs) in Bangalore

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News